| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Expression in Acute Myeloid Leukemia1 Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, 2 Department of Molecular Genetics, 3 College of Pharmacy, and 4 Department of Internal Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; 5 The Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, North Carolina; 6 Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany; and 7 German Cancer Research Center, Heidelberg, Germany
Requests for reprints: Björn Hackanson, Universitätsklinik Freiburg, Abteilung Hämatologie/Onkologie, Hugstetterstrasse 55, 79106 Freiburg, Germany. Phone: 49-761-2707715; Fax: 49-761-2703697; E-mail: bjoern.hackanson{at}uniklinik-freiburg.de or Christoph Plass, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg. Phone: 49-6221-42-3300; Fax: 49-6221-42-3359; E-mail: c.plass{at}dkfz-heidelberg.de.
Key Words: AML epigenetic microRNA
Functional loss of CCAAT/enhancer binding protein
(C/EBP
), a master regulatory transcription factor in the hematopoietic system, can result in a differentiation block in granulopoiesis and thus contribute to leukemic transformation. Here, we show the effect of epigenetic aberrations in regulating C/EBP
expression in acute myeloid leukemia (AML). Comprehensive DNA methylation analyses of the CpG island of C/EBP
identified a densely methylated upstream promoter region in 51% of AML patients. Aberrant DNA methylation was strongly associated with two generally prognostically favorable cytogenetic subgroups: inv(16) and t(15;17). Surprisingly, while epigenetic treatment increased C/EBP
mRNA levels in vitro, C/EBP
protein levels decreased. Using a computational microRNA (miRNA) prediction approach and functional studies, we show that C/EBP
mRNA is a target for miRNA-124a. This miRNA is frequently silenced by epigenetic mechanisms in leukemia cell lines, becomes up-regulated after epigenetic treatment, and targets the C/EBP
3' untranslated region. In this way, C/EBP
protein expression is reduced in a posttranscriptional manner. Our results indicate that epigenetic alterations of C/EBP
are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor. [Cancer Res 2008;68(9):3142–51]
This article has been cited by other articles:
![]() |
T. Pabst and B. U. Mueller Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2009; 15(17): 5303 - 5307. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Agirre, A. Vilas-Zornoza, A. Jimenez-Velasco, J. I. Martin-Subero, L. Cordeu, L. Garate, E. San Jose-Eneriz, G. Abizanda, P. Rodriguez-Otero, P. Fortes, et al. Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia Cancer Res., May 15, 2009; 69(10): 4443 - 4453. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Figueroa, B. J. Wouters, L. Skrabanek, J. Glass, Y. Li, C. A. J. Erpelinck-Verschueren, A. W. Langerak, B. Lowenberg, M. Fazzari, J. M. Greally, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features Blood, March 19, 2009; 113(12): 2795 - 2804. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roman-Gomez, X. Agirre, A. Jimenez-Velasco, V. Arqueros, A. Vilas-Zornoza, P. Rodriguez-Otero, I. Martin-Subero, L. Garate, L. Cordeu, E. San Jose-Eneriz, et al. Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia J. Clin. Oncol., March 10, 2009; 27(8): 1316 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hackanson, H. Becker, T. Berg, M. Binder, C. Dierks, J. Duque-Afonso, M. D. Lairmore, H. S. Schafer, M. Schnitzler, R. Zeiser, et al. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors Cancer Res., July 15, 2008; 68(14): 5512 - 5518. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |